Targovax ASA: Interim report third quarter 2015
(Thomson Reuters ONE) -
* Next development phase established via merger, capital increase and new
partnerships
* Merged with Finnish company Oncos Therapeutics in July, establishing a
combined company with two promising technology platforms and diversified
pipeline
* Successfully raised NOK 200 million to finance ongoing studies under the TG
and ONCOS platforms
* Third quarter 2015 operating expenditures of NOK 29 million
* Phase II trial TG01 in pancreatic cancer and the preparation of Phase I/II
trial ONCOS-102 in mesothelioma progressed as planned
* Signed agreements with US based Ludwig Cancer Research (LICR) and the
Cancer Research Institute (CRI) to evaluate ONCOS-102 in combination with
other immunotherapies
* Entered into collaboration with Czech biotech company Sotio to study
combination of ONCOS-102 and Sotio's dendritic cell therapy
"The combination with Oncos expanded our technology platform, pipeline and
market opportunities. It also brought together an experienced, international
management team and a board with extensive pharmaceutical and commercial
experience. We are looking forward to further developing our TG and ONCOS
technologies supported by new collaborations with internationally renowned
partners", says Gunnar Gårdemyr, CEO of Targovax.
Targovax is the owner of two established technologies with promising phase I
data; TG01 and ONCOS-102. TG01 is the only RAS-specific vaccine currently in
development, while ONCOS-102 is the only viral cancer immunotherapy shown to
induce tumor specific cellular immunity in humans. With these two technologies,
Targovax has established a solid platform for further development of its
clinical stage immune-oncology technologies and targeted immunotherapy
treatments for cancer patients.
The TG01 Pancreas cancer Phase II trials are progressing as planned. In the
first quarter 2015, Targovax decided to expand the study with a second cohort of
up to 13 patients in order to optimize the vaccine regimen. The study centres
are open for recruitment and patients are being treated. The TG02 Colorectal
cancer open-label study including 20 patients is planned to start during the
first half of 2016
ONCOS-102 Mesothelioma, a randomized phase II open label study planned to
include 30 patients, is set to commence in the first half of 2016, while the
ONCOS-102 Melanoma open-label study involving 12 patients, will commence during
the second half next year.
To finance the ongoing development and exploratory studies under its TG- and the
ONCOS platforms, Targovax raised NOK 200 million in a private placement on the
back of the July merger. Third quarter 2015 operating expenditures of NOK 29
million reflects the investment phase the company.
In addition to ongoing internal studies, Targovax collaborates with external
scientific partners. In November, the company entered an agreement with US based
Ludwig Cancer Research (LICR) and the Cancer Research Institute (CRI) to
evaluate ONCOS-102 in combination with other immunotherapies such as checkpoint
inhibitors. Recently, Targovax also entered into an agreement with the Czech
biotech company Sotio to run a collaboration study combining ONCOS-102 and
Sotio's dendritic cell therapy to evaluate the safety and tolerability in the
treatment of advanced prostate cancer.
Reporting material
The quarterly report and the presentation material will be available at this
time at www.targovax.com.
Presentation at 10:00 CET
A presentation of the results will be held at 10:00 CET at Hotel Continental
Conference Centre, Stortingsgaten 24/26, Oslo, Norway. CEO Gunnar Gårdemyr, CFO
Øystein Soug and CMO Magnus Jäderberg will be representing the company.
Following the quarterly presentation Dr. Jäderberg will give a 20-30 minute
presentation on the history of cancer treatments and immunotherapy.
Conference call
At 14:00 CET (08:00 EST), Targovax will host a telephone conference, including a
presentation of the results, following with a Q&A session. Call in details
below. Please make sure to dial in at least 5-10 minutes ahead of time to
complete your registration.
Participant information:
Call in number:
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +472350 0559
UK Toll-Free Number: 08082370030
UK Toll Number: +442031394830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077
See attached list for more dial in numbers.
http://wpc.1726.planetstream.net/001726/FEL_Events_International_Access_List.pdf
Access code:
68554865#
For further information, please contact
Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email: ggardemyr(at)targovax.com
Øystein Soug
CFO
Phone: +47 906 56 525
Email: oystein.soug(at)targovax.com
About Targovax - Arming the patient's immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aim to become a leader in its area. The
company is currently developing two complementary and highly targeted approaches
in immuno-oncology:
Oncos 102 is a virus-based immunotherapy platform based on engineered oncolytic
viruses armed with potent immune-stimulating transgenes targeting solid tumors.
This treatment may reinstate the immune system's capacity to recognize and
attack cancer cells.
TG01 is a peptide-based immunotherapy platform targeting the difficult to treat
RAS mutations found in more than 85% of pancreatic cancers and 20-30% of all
cancers. Targovax works towards demonstrating that TG01 will prolong time to
cancer progression, increase survival and improve safety and tolerability.
The product candidates will be developed in combination with multiple treatments
in several cancer indications, including checkpoint inhibitors. Targovax also
has a number of other cancer immune therapy candidates in the early stage of
development. For more information visit www.targovax.com.
Targovax Q3 Report:
http://hugin.info/171039/R/1969473/719842.pdf
Targovax Q3 Presentation:
http://hugin.info/171039/R/1969473/719843.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
[HUG#1969473]
Unternehmensinformation / Kurzprofil:
Datum: 26.11.2015 - 07:00 Uhr
Sprache: Deutsch
News-ID 435835
Anzahl Zeichen: 7437
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 321 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax ASA: Interim report third quarter 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
